GlassScriptPhysician profile
Michael A Flores
NPI 1649289497
$3,416.15
in general payments reported to CMS, 2019-2025
26 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $392 · 2021: $1,131 · 2022: $314 · 2023: $271 · 2024: $480 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.99 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $937.50 | 2021 | |
| Novo Nordisk INC | $315.19 | 2020-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $300.74 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $249.48 | 2021-2025 | |
| Allergan, INC. | $171.58 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $159.30 | 2022-2024 | Farxiga, Breztri |
| Amarin Pharma, INC. | $148.53 | 2020 | |
| Ironshore Pharmaceuticals INC. | $144.39 | 2022-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $139.11 | 2023-2025 | Rexulti, Abilify Maintena |
| Bard Peripheral Vascular, INC. | $136.98 | 2019 | |
| Corium, LLC | $77.59 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.22 | 2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $65.95 | 2023-2024 | Austedo Xr, Uzedy |
| Collegium Pharmaceutical, INC. | $64.17 | 2025 | Jornay Pm |
| Novartis Pharmaceuticals Corporation | $60.17 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $59.12 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.95 | 2019-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $42.41 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $41.26 | 2022-2023 | |
| Pfizer INC. | $38.49 | 2019-2020 | |
| Amgen INC. | $33.68 | 2023-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.69 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.06 | 2025 | Cobenfy |
| Genentech USA, INC. | $17.90 | 2021 | |
| Astellas Pharma US INC | $17.83 | 2022 | |
| Sunovion Pharmaceuticals INC. | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.